Search results
Results From The WOW.Com Content Network
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022. [ 4][ 5] Novartis manufactures the drugs clozapine (Clozaril), diclofenac (Voltaren; sold to ...
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
Takeda Midosuji Building, headquarters of Takeda Pharmaceutical Company, in Chuo-ku, Osaka, Japan. Takeda Pharmaceuticals was founded in 1781, and was incorporated on January 29, 1925. [ 12] One of the firm's mainstay drugs is Actos ( pioglitazone ), a compound in the thiazolidinedione class of drugs used in the treatment of type 2 diabetes.
August 7, 2024 at 11:23 AM. By Sriparna Roy. (Reuters) -The U.S. Food and Drug Administration has approved the use of Novartis' drug to reduce excess protein in the urine of patients with a type ...
(Reuters) -Drugmaker Novartis AG said it will acquire MorphoSys AG, a developer of cancer treatments, for 2.7 billion euros ($2.9 billion), adding a promising rare bone-marrow cancer treatment ...
January 9, 2024 at 2:50 AM. (Reuters) -Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar ...
Jörg Reinhardt. Jörg Reinhardt (born 11 March 1956) is a German businessman who has been the chairman of the board of directors of the Swiss pharmaceutical group Novartis AG since 2013. [1] [2] Since 2017, he has also been a member of the board of directors of the Swiss reinsurance group Swiss Re. [3]
By David Carnevali (Reuters) -Drug maker Novartis AG is in advanced talks to acquire MorphoSys AG, a developer of cancer treatments that has a market value of 1.6 billion euros ($1.7 billion), two ...